How much profit has aTyr Pharma made this year?
aTyr Pharma has made -68.82 M USD this year.
aTyr Pharma Net Income 2025
aTyr Pharma Net Income
-68.82 M USD
Ticker
ATYR
ISIN
US0021202025
WKN
A2PM86
In 2025, aTyr Pharma's profit amounted to -68.82 M USD, a -12.04% increase from the -78.23 M USD profit recorded in the previous year.
The aTyr Pharma Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2030e | 540.68 |
| 2029e | 391.28 |
| 2028e | 164.53 |
| 2027e | 37.95 |
| 2026e | -53.62 |
| 2025e | -68.82 |
| 2024e | -78.23 |
| 2023 | -50.39 |
| 2022 | -45.34 |
| 2021 | -33.77 |
| 2020 | -16.22 |
| 2019 | -23.6 |
| 2018 | -34.52 |
| 2017 | -48.21 |
| 2016 | -57.86 |
| 2015 | -47.99 |
| 2014 | -24.77 |
| 2013 | -21.65 |
| 2012 | -17.61 |
aTyr Pharma Revenue, EBIT, Net Income US0021202025 · A2PM86
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into aTyr Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by aTyr Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects aTyr Pharma’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of aTyr Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into aTyr Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing aTyr Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on aTyr Pharma’s growth potential.
aTyr Pharma Revenue, EBIT and net profit per share
| Date | aTyr Pharma Revenue | aTyr Pharma EBIT | aTyr Pharma Net Income |
|---|---|---|---|
| 2030e | 904.49 M undefined | 0 undefined | 540.68 M undefined |
| 2029e | 627.31 M undefined | 429.34 M undefined | 391.28 M undefined |
| 2028e | 332.79 M undefined | 172.56 M undefined | 164.53 M undefined |
| 2027e | 165.45 M undefined | 29.61 M undefined | 37.95 M undefined |
| 2026e | 38.2 M undefined | -65.99 M undefined | -53.62 M undefined |
| 2025e | 2.91 M undefined | -73.75 M undefined | -68.82 M undefined |
| 2024e | 241,964.4 undefined | -72.08 M undefined | -78.23 M undefined |
| 2023 | 353,000 undefined | -54.92 M undefined | -50.39 M undefined |
| 2022 | 10.39 M undefined | -46.4 M undefined | -45.34 M undefined |
| 2021 | 0 undefined | -34.02 M undefined | -33.77 M undefined |
| 2020 | 10.46 M undefined | -15.91 M undefined | -16.22 M undefined |
| 2019 | 422,000 undefined | -22.98 M undefined | -23.6 M undefined |
| 2018 | 0 undefined | -32.82 M undefined | -34.52 M undefined |
| 2017 | 0 undefined | -47.15 M undefined | -48.21 M undefined |
| 2016 | 0 undefined | -57.94 M undefined | -57.86 M undefined |
| 2015 | 0 undefined | -47.62 M undefined | -47.99 M undefined |
| 2014 | 0 undefined | -23.55 M undefined | -24.77 M undefined |
| 2013 | 0 undefined | -19.54 M undefined | -21.65 M undefined |
| 2012 | 0 undefined | -12.6 M undefined | -17.61 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2012 | 0 USD | -12.6 M USD | -17.61 M USD |
| 2013 | 0 USD | -19.54 M USD | -21.65 M USD |
| 2014 | 0 USD | -23.55 M USD | -24.77 M USD |
| 2015 | 0 USD | -47.62 M USD | -47.99 M USD |
| 2016 | 0 USD | -57.94 M USD | -57.86 M USD |
| 2017 | 0 USD | -47.15 M USD | -48.21 M USD |
| 2018 | 0 USD | -32.82 M USD | -34.52 M USD |
| 2019 | 422,000 USD | -22.98 M USD | -23.6 M USD |
| 2020 | 10.46 M USD | -15.91 M USD | -16.22 M USD |
| 2021 | 0 USD | -34.02 M USD | -33.77 M USD |
| 2022 | 10.39 M USD | -46.4 M USD | -45.34 M USD |
| 2023 | 353,000 USD | -54.92 M USD | -50.39 M USD |
| 2024e | 241,964.4 USD | -72.08 M USD | -78.23 M USD |
| 2025e | 2.91 M USD | -73.75 M USD | -68.82 M USD |
| 2026e | 38.2 M USD | -65.99 M USD | -53.62 M USD |
| 2027e | 165.45 M USD | 29.61 M USD | 37.95 M USD |
| 2028e | 332.79 M USD | 172.56 M USD | 164.53 M USD |
| 2029e | 627.31 M USD | 429.34 M USD | 391.28 M USD |
| 2030e | 904.49 M USD | 0 USD | 540.68 M USD |
aTyr Pharma stock margins US0021202025 · A2PM86
The aTyr Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of aTyr Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for aTyr Pharma.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the aTyr Pharma's sales revenue. A higher gross margin percentage indicates that the aTyr Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the aTyr Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the aTyr Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the aTyr Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the aTyr Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the aTyr Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
aTyr Pharma Margin History
| aTyr Pharma Gross margin | aTyr Pharma Profit margin | aTyr Pharma EBIT margin | aTyr Pharma Profit margin |
|---|---|---|---|
| 2030e | 0 % | 0 % | 59.78 % |
| 2029e | 0 % | 68.44 % | 62.37 % |
| 2028e | 0 % | 51.85 % | 49.44 % |
| 2027e | 0 % | 17.9 % | 22.94 % |
| 2026e | 0 % | -172.77 % | -140.38 % |
| 2025e | 0 % | -2,533.43 % | -2,364 % |
| 2024e | 0 % | -29,791.29 % | -32,332.93 % |
| 2023 | 0 % | -15,557.79 % | -14,274.5 % |
| 2022 | 0 % | -446.79 % | -436.53 % |
| 2021 | 0 % | 0 % | 0 % |
| 2020 | 0 % | -152.19 % | -155.18 % |
| 2019 | 0 % | -5,445.02 % | -5,593.13 % |
| 2018 | 0 % | 0 % | 0 % |
| 2017 | 0 % | 0 % | 0 % |
| 2016 | 0 % | 0 % | 0 % |
| 2015 | 0 % | 0 % | 0 % |
| 2014 | 0 % | 0 % | 0 % |
| 2013 | 0 % | 0 % | 0 % |
| 2012 | 0 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2012 | 0 % | 0 % | 0 % |
| 2013 | 0 % | 0 % | 0 % |
| 2014 | 0 % | 0 % | 0 % |
| 2015 | 0 % | 0 % | 0 % |
| 2016 | 0 % | 0 % | 0 % |
| 2017 | 0 % | 0 % | 0 % |
| 2018 | 0 % | 0 % | 0 % |
| 2019 | 0 % | -5,445.02 % | -5,593.13 % |
| 2020 | 0 % | -152.19 % | -155.18 % |
| 2021 | 0 % | 0 % | 0 % |
| 2022 | 0 % | -446.79 % | -436.53 % |
| 2023 | 0 % | -15,557.79 % | -14,274.5 % |
| 2024e | 0 % | -29,791.29 % | -32,332.93 % |
| 2025e | 0 % | -2,533.43 % | -2,364 % |
| 2026e | 0 % | -172.77 % | -140.38 % |
| 2027e | 0 % | 17.9 % | 22.94 % |
| 2028e | 0 % | 51.85 % | 49.44 % |
| 2029e | 0 % | 68.44 % | 62.37 % |
| 2030e | 0 % | 0 % | 59.78 % |
aTyr Pharma Aktienanalyse
What does aTyr Pharma do?
aTyr Pharma Inc is a biotechnology company based in San Diego, California. Founded in 2005, the company has gained a lot of attention in recent years for its focus on developing drugs based on proteomics, the analysis of proteins. The idea for aTyr came from the realization that there are a variety of proteins that can be used as a basis for developing new drugs. The company has developed a unique proteomics platform that allows for the identification and utilization of previously undiscovered proteins to understand biological processes and develop new drugs for diseases. aTyr specializes in the discovery and development of proteins associated with rare but difficult-to-treat diseases. This includes rare muscle diseases and lung diseases. The company collaborates closely with clinicians and scientists to advance its research and development. aTyr's business model is based on the development of new drugs based on proteomics, with a focus on rare diseases that are often neglected. The goal is to improve the quality of life for patients by developing new and innovative drugs. aTyr has various divisions, including therapeutic proteins and diagnostics. The company has a number of drugs in development targeting different diseases. This includes Resolaris, a protein focused on rare muscle diseases, and ATYR1923, developed for the treatment of lung diseases. Resolaris is a novel protein targeting rare muscle diseases such as FSHD and LGMD. It is currently being tested in clinical trials and has the potential to significantly improve the quality of life for patients with these severe conditions. The company is also developing ATYR1923, a protein for the treatment of lung diseases such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Overall, aTyr Pharma is an innovative company focused on the development of novel drugs based on proteomics. With its unique proteomics platform, the company has the potential to identify and utilize previously undiscovered proteins to understand biological processes and develop new drugs for diseases. With its various divisions, including therapeutic proteins and diagnostics, the company has the potential to improve the treatment of rare and difficult-to-treat diseases and enhance the lives of patients worldwide. aTyr Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding aTyr Pharma's Profit Margins
The profit margins of aTyr Pharma represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of aTyr Pharma's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating aTyr Pharma's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
aTyr Pharma's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When aTyr Pharma’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about aTyr Pharma stock
How has the profit developed compared to last year?
The profit has increased by -12.04% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does aTyr Pharma publish its earnings?
aTyr Pharma publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of aTyr Pharma?
The profits of aTyr Pharma are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of aTyr Pharma?
You can learn more about the earnings of aTyr Pharma by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does aTyr Pharma pay?
Over the past 12 months, aTyr Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, aTyr Pharma is expected to pay a dividend of 0 USD.
What is the dividend yield of aTyr Pharma?
The current dividend yield of aTyr Pharma is .
When does aTyr Pharma pay dividends?
aTyr Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of aTyr Pharma?
aTyr Pharma paid dividends every year for the past 0 years.
What is the dividend of aTyr Pharma?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is aTyr Pharma located?
aTyr Pharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von aTyr Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of aTyr Pharma from 1/24/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/24/2025.
When did aTyr Pharma pay the last dividend?
The last dividend was paid out on 1/24/2025.
What was the dividend of aTyr Pharma in the year 2024?
In the year 2024, aTyr Pharma distributed 0 USD as dividends.
In which currency does aTyr Pharma pay out the dividend?
The dividends of aTyr Pharma are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The aTyr Pharma stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von aTyr Pharma
Our stock analysis for aTyr Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of aTyr Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.